DSUR (Development Safety Update Report)
Last reviewedA Development Safety Update Report (DSUR) is the annual safety report for a drug in clinical development. It presents the safety information from all clinical trials of the investigational product that were ongoing or completed during the reporting period, and is submitted to the health authorities overseeing those trials.
Key facts
| Guideline | ICH E2F |
|---|---|
| Applies to | Investigational drugs and biologics, from the first clinical trial authorisation until development ends |
| Frequency | Once a year |
| Reporting period starts | The Development International Birth Date (DIBD), the date of the first trial authorisation in any country |
| Due | No later than 60 calendar days after the data lock point |
| Post-approval counterpart | PBRER (called PSUR in the EU) |
What a DSUR contains
The report summarises the status of the clinical programme, estimated cumulative exposure, interval line listings of serious adverse reactions, cumulative summary tabulations of serious adverse events, significant findings from trials and other sources, and an overall safety assessment with a summary of important risks.
Sources
Read more
Part of our guide to Pharmacovigilance Aggregate Reports: DSUR, PBRER, PSUR and PADER

